Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects

NCT02696291 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped Product development halted for business reasons.

Conditions

Viral Infection

Interventions

DRUG: UV-4B 30 mg oral solution
DRUG: UV-4B 75 mg oral solution
DRUG: UV-4B 150 mg oral solution
DRUG: UV-4B X mg (dose to be determined) oral solution
DRUG: UV-4B Y mg (dose to be determined) oral solution
DRUG: Placebo

Sponsor

Emergent BioSolutions

Collaborators

[object Object]